Stock Ratings / Health Care / PAHC / insiders

GPCR (42) OCUL (37) INVA (75) ETON (62) ⌘ Pro Terminal →

Phibro Animal Health Corporation (Class A) (PAHC) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$38.86 +2.59% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.97

Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $1.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PAHC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-01, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $38.86 (+2.59% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 14/20. Across 1016 tracked Health Care issuers, PAHC ranks #108 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PAHC compare to GPCR and OCUL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable C+ (68/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, GPCR (Structure Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -19.5%, cap $1.56B) and OCUL (Ocular Therapeutix Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.61B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while INVA leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PAHC?

▼

Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $38.97 (+0.28%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.6%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY PAHC SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (22% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 56.9 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (21% of score)

Altman Z-Score 2.87 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Cash Engine Quality12/20 pts (-8 pt drag)

Capital intensity & 8.5% operating margin leave 8 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$38.30+1.4% Next Q

Q2 (-2Q)

Grade C+$38.82-0.1% Next Q

Q3 (-1Q)

Grade C+$38.80+0.2% Next Q

Current

Grade C+$38.86+1.8% Hist 90D α

Trajectory: C (60) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PAHC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, PAHC faces multiple-compression risk if 32.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 28.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($36.99) or 200D SMA ($41.26) invalidates the momentum regime and cuts Target Base ($40.61) toward Bear Floor ($31.68).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PAHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PAHC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

PAHC Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (PAHC)

No recent open-market Form 4 cluster sales or emergency dumps flagged on PAHC. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PAHC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.93%⚡ TESTING RESISTANCE

2026-10-30O $39.38H $39.95L $38.49C $38.86VOL 182.8K

RES: $40.91SUP: $34.09SMA50: $36.99SMA200: $41.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAHC Butterfly Map → + Track PAHC →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)

Health Care Rank #108 of 1016 ⚔️ GPCR vs PAHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAHC vs. GPCR, OCUL, INVA, ETON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #108 by composite RQD confidence (68/100, grade C+) and #300 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while INVA leads on capital efficiency and profitability with 14.7% ROIC and 74.8% gross margin. INVA currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with PAHC at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAHC ACTIVE Phibro Animal Health Corporation (Class A)	C+	68/100	32.7x	30.9%	9.9%	+2.59%	$1.58B	Benchmark Subject
GPCR Structure Therapeutics Inc.	D-	42/100	—	—	-19.5%	+2.14%	$1.56B	/gpcr-vs-pahc →
OCUL Ocular Therapeutix Inc.	D-	37/100	—	87.3%	-35.0%	+0.27%	$1.61B	/ocul-vs-pahc →
INVA Innoviva Inc.	B	75/100	—	74.8%	14.7%	+0.90%	$1.54B	/inva-vs-pahc →
ETON Eton Pharmaceuticals Inc.	C	62/100	—	53.5%	-0.9%	+3.61%	$1.53B	/eton-vs-pahc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.30B	$48.3M	$80.1M	$80.1M	$1.41B	$603.6M
FY2024 (FY)	2024-06-30	$1.02B	$2.4M	$87.6M	$87.6M	$1.29B	$622.9M
FY2023 (FY)	2023-06-30	$977.9M	$32.6M	$13.3M	$13.3M	—	—

3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PAHC compare to GPCR and OCUL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PAHC?

Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?

PAHC last traded at $38.86 (+2.59% on volume of 100,844 shares), positioning the stock +5.06% above its 50-day simple moving average ($36.99) and -5.82% below its 200-day simple moving average ($41.26). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.3% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.6% ($35.91 to $41.81).

PAHC Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are PAHC insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies PAHC leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: PAHC RQD Cockpit PAHC 12M Forecast PAHC Earnings & Move PAHC Dividends & DRIP PAHC Insiders & 13F PAHC Whale Options PAHC Profit Sankey PAHC News & Why